Ars Pharmaceuticals Inc (SPRY) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ars Pharmaceuticals Inc   (NASDAQ: SPRY)

Ars Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Ars Pharmaceuticals Inc in the second quarter 2026?
Ars Pharmaceuticals Inc recorded a cumulative net loss of $-215 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -256.67%.

Within the Major Pharmaceutical Preparations industry 336 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 3054 to 3676.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change -93.49 % -73.22 % -55.51 % -26.53 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -215 -198 -171 -80 -48
Return On Equity (TTM) -256.67 % -153.61 % -100.29 % -38.77 % -21.85 %
SPRY's Total Ranking # 3676 # 3054 # 3153 # 2846 # 2455
Equity (TTM) in Millions 13 61 114 148 192
Seq. Equity Change -79.59 % -46.34 % -22.62 % -23.22 % -16.01 %
Seq. Net Income Change - - - - -

Back to SPRY Management Effectiveness >> SPRY's 5 Years Annual ROE >> Compare SPRY ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 337
Sector # 705
Overall # 3676

Return On Equity Statistics
High Average Low
3.57 %
-42.82 %
-256.67 %
(Dec 31 2024)   (Jun 30 2026)



  News about Ars Pharmaceuticals Inc Return on Equity ROE

A Breath of Fresh Air ARS Pharmaceuticals Needle-Free Solution for Allergy Emergencies,

ARS Pharmaceuticals Innovates Allergy Management with Needle-Free Epinephrine Nasal Spray SummaryARS Pharmaceuticals, a biopharmaceutical firm committed to advancing allergen protection for at-risk populations, has taken significant strides towards revolutionizing allergy treatment with its product, neffy, the first and only needle-free treatment for Type I allergic reactions including anaphylaxis. This pioneering epinephrine nasal spray has garnered notable attention both in the U.S. and Europe for its potential implications in managing severe allergic reactions via a more user-friendly administration method. Launch of Pre-Ordering Service Starting ahead of its anticipated market availability by late September, ARS Pharmaceuticals has launched a pre-ordering service. This initiative allows patients to secure prescriptions for neffy through their current healthcare providers or through virtual consultations with physicians. The pre-ordering service is designed to streamline patient access to this groundbreaking treatment, ensuring timely availability once the product hits the market.



SPRY Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 114 257 231 273 314
Y / Y Equity Change -55.51 % 11.28 % -15.44 % -13.04 % -
Net Income in Millions -171 8 -54 -35 -89
Y / Y Net Income Change - - - - -
Return On Equity -149.92 % 3.11 % -23.56 % -12.71 % -28.51 %

Back to SPRY Management Effectiveness >> SPRY's 5 Years Annual ROE >> Compare SPRY ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
SPRY's' Return on Equity at Yahoo Finance
SPRY's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SPRY's Competitors
Subscribers only: Roe for Ars Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for SPRY's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-03T12:16:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.